Mr. Rabin Rai
Manager Assistant
International Trade Dept.
Address:
Zhongxin Mansion 5f, No. 17 Of Baidi Road, Nankai District, Tianjin, P. R. China
Telephone:
Zip Code:
Fax:
| Please sign in to view contact details |
Account Registered in:
2005
Business Range:
Health & Medicine
Business Type:
Other
Company Introduction
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited is the sole listed company in China that has listed both S-shares in Singapore and A-shares in China. Owning 52 branch companies and subsidiaries with holding and minor stakes, it is a large inter-regional and inter-trade pharmaceutical group with investment and holding functions.
The business of Zhong Xin covers a wide range of fields ...
The business of Zhong Xin covers a wide range of fields ...
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited is the sole listed company in China that has listed both S-shares in Singapore and A-shares in China. Owning 52 branch companies and subsidiaries with holding and minor stakes, it is a large inter-regional and inter-trade pharmaceutical group with investment and holding functions.
The business of Zhong Xin covers a wide range of fields including Chinese patent drugs, Chinese medicine tablets, Chinese medicinal materials, bioengineering drugs, crude chemical drugs and preparations, and nutritious and health products, with nearly 700 product varieties in 20-odd types of preparations. The Company has built up the biggest directly operated chain store and logistics distribution system in China, with a marketing network extending to more than 30 countries and regions as well as all across China.
In recent years, the Group has accelerated the pace of technical renovation in the direction of integration with the advanced level in the world. It undertook a total of 20 key technological research projects of the State and Tianjin Municipality, and popularized 20 new technologies and scored more than 30 technological achievements. All these cushioned super-high speed development of the enterprise. By 2003, the Company had gross assets of 3. 7 billion yuan and net assets of 1. 75 billion yuan. Its sales revenue in 2003 reached 3. 5 billion yuan, ranking second in the industry of the whole country.
In 2002, Zhong Xin Pharmaceutical worked out the medium and long-term development strategy, I. E. Improving seven bases, building two systems and implementing five strategies.
The seven bases are: Modern Chinese medicine industrial park; Super-critical Chinese medicine extraction and pill preparation base; Industrial base of oral solid preparation of Chinese medicine; Standard medicinal materials production base; Crude chemical drug and preparation production base; Cephalosporin production base; And Hualida Biological Industrial Park.
The two systems are: Computer ERP information management system, and domestic and international logistics system.
The five strategies are: System and mechanism innovation strategy; Capital operation strategy; Human resources strategy; Research and development strategy; And market development strategy.
Zhong Xin Pharmaceutical has taken the construction of the modern Chinese medicine strategy. It has accelerated the construction of the seven bases as a whole so as to build itself into a large state-controlled joint-stock enterprise and a multinational pharmaceutical group with international competitiveness that bases its core competitiveness on modern Chinese medicines and at the same time develops chemical medicines and bio-medicines and owns a complete industrial chain, product chain and human resource chain.
The business of Zhong Xin covers a wide range of fields including Chinese patent drugs, Chinese medicine tablets, Chinese medicinal materials, bioengineering drugs, crude chemical drugs and preparations, and nutritious and health products, with nearly 700 product varieties in 20-odd types of preparations. The Company has built up the biggest directly operated chain store and logistics distribution system in China, with a marketing network extending to more than 30 countries and regions as well as all across China.
In recent years, the Group has accelerated the pace of technical renovation in the direction of integration with the advanced level in the world. It undertook a total of 20 key technological research projects of the State and Tianjin Municipality, and popularized 20 new technologies and scored more than 30 technological achievements. All these cushioned super-high speed development of the enterprise. By 2003, the Company had gross assets of 3. 7 billion yuan and net assets of 1. 75 billion yuan. Its sales revenue in 2003 reached 3. 5 billion yuan, ranking second in the industry of the whole country.
In 2002, Zhong Xin Pharmaceutical worked out the medium and long-term development strategy, I. E. Improving seven bases, building two systems and implementing five strategies.
The seven bases are: Modern Chinese medicine industrial park; Super-critical Chinese medicine extraction and pill preparation base; Industrial base of oral solid preparation of Chinese medicine; Standard medicinal materials production base; Crude chemical drug and preparation production base; Cephalosporin production base; And Hualida Biological Industrial Park.
The two systems are: Computer ERP information management system, and domestic and international logistics system.
The five strategies are: System and mechanism innovation strategy; Capital operation strategy; Human resources strategy; Research and development strategy; And market development strategy.
Zhong Xin Pharmaceutical has taken the construction of the modern Chinese medicine strategy. It has accelerated the construction of the seven bases as a whole so as to build itself into a large state-controlled joint-stock enterprise and a multinational pharmaceutical group with international competitiveness that bases its core competitiveness on modern Chinese medicines and at the same time develops chemical medicines and bio-medicines and owns a complete industrial chain, product chain and human resource chain.
